logo-loader
Motif Bio PLC

Motif Bio gets confirmation of requirements for new iclaprim trial

Motif has now received the minutes of its Type B meeting with the US Food and Drug Administration in September

Motif Bio PLC -

Motif Bio PLC (LON:MTFB) has received official confirmation of the parameters of a new trial to get US approval for its iclaprim antibiotic.

Minutes of a Type B meeting between Motif and US Food and Drug Administration in September indicated a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with bacterial pneumonia (HABP/VABP), along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application.

Motif Bio repeated that it would take several years to enrol and complete a HABP/VABP Phase III trial and cost tens of millions of dollars hence its decision to either find a partner to pay for the trial or else dispose of iclaprim to a firm with deeper pockets.

The FDA is concerned about possible liver toxicity with iclaprim, something that emerged following the submission of trial data from two phase III assessments of the drug.

Graham Lumsden, chief executive, said: "We now have confirmation of what will be required to progress iclaprim towards a potential approval.

"The company is working hard to find a partner or other entity to complete the HABP/VABP Phase III trial, commercialise iclaprim and ensure the best outcome for shareholders in Motif Bio."

Quick facts: Motif Bio PLC

Price: 0.64 GBX

Market: AIM
Market Cap: £2.19 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio's Graham Lumsden updates on FDA discussions and iclaprim potential

Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim. Feedback from that meeting is expected in...

on 24/5/19

RNS

Second Price Monitoring Extn

2 weeks, 3 days ago

Price Monitoring Extension

2 weeks, 3 days ago

Change of Adviser

2 weeks, 3 days ago

Conditional Placing

2 weeks, 4 days ago

Second Price Monitoring Extn

2 weeks, 6 days ago

Price Monitoring Extension

2 weeks, 6 days ago

Half-year Report

2 weeks, 6 days ago

2 min read